Qiagen N.V. is supported by new product launches and automation initiatives poised to drive revenue growth. See why I rate ...

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of ...

In most modern cells, DNA stores the genetic blueprint, and proteins replicate, repair and build from those blueprints. At ...

Synucleinopathies are a group of neurodegenerative disorders that include serious conditions such as Parkinson's disease and ...

Scientists have harnessed artificial-intelligence models to create synthetic CRISPR proteins that edit the genome more ...

QIAGEN N.V. today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More ...

A little-known RNA molecule found only in women may influence immunity, infection severity, and autoimmune risk.

Controlling ribosomal RNA could help researchers target diseases driven by too little or too much protein production.

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...

Researchers used AI to create variants of a CRISPR-Cas12-like nuclease, some of which show increased editing activity ...

Qiagen (QGEN) reported $540.42 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 3.7%. EPS of $0.62 for the same period compares to $0.64 a year ago.

Lightweight lithium metal is a heavy-hitting critical mineral, serving as the key ingredient in the rechargeable batteries that power phones, laptops, electric vehicles and more. As ubiquitous as ...